September 2010- Volume 6, Issue 9

September 2010

In this Issue

Research & Development

7,000 points of light

7,000 points of light

Sigma Life Science and Boston University awarded NHLBI grant to probe samples from Framingham Heart Study for biomarkers in cardiovascular disease

Jumping into the game

Jumping into the game

Envoy to seek new Parkinson’s disease therapy with Scripps Research Institute

Signaling the pathway to antibody development

Signaling the pathway to antibody development

NovImmune enters into exclusive antibody licensing agreement with Genentech

Striking a nerve

Striking a nerve

Gladstone, Danish drugmaker Lundbeck sign neurological disease research agreement

The French connection

The French connection

Seeking to acquire Genzyme, sanofi-aventis goes public with a nearly $20 billion cash offer

Government Watch

The big decision on Bilski

The big decision on Bilski

Supreme Court patent ruling on Bilski means much for diagnostics, less for pharma

DTC genetic testing faces federal fire

DTC genetic testing faces federal fire

GAO investigators say DNA tests give bogus results, mislead consumers; FDA launches probe of several companies

Is close enough good enough for medicine?

Is close enough good enough for medicine?

Proposal to allow biosimilars takes heat at Congressional caucus hearing

Instruments & Informatics

A VisEn-ary acquisition

A VisEn-ary acquisition

PerkinElmer’s acquisition of VisEn Medical will add in vivo molecular imaging capabilities to enhance preclinical research

A collaboration in the Cleve

A collaboration in the Cleve

EMD Millipore and Cleveland Clinic collaborate on method to rapidly stain and assess tissue

Automation solution enables protein purification

Automation solution enables protein purification

PhyNexus, Tecan collaborating on development of standard processes

Axela’s acquisition of Xceed Molecular hits snag

Axela’s acquisition of Xceed Molecular hits snag

Plan to create a powerhouse in robust and easy-to-use systems for translational medicine put on hold as recession hits Canadian life sciences companies hard

Illumina shines light on Helixis acquisition

Illumina shines light on Helixis acquisition

Company announces purchase, launch of new PCR product in Q2 financial report

Omics & Systems Biology

Partnership is primed and ready

Partnership is primed and ready

FivePrime Therapeutics partners with GSK on skeletal muscle disorders

AB SCIEX and ETH Zurich Institute join forces to advance systems biology

AB SCIEX and ETH Zurich Institute join forces to advance systems biology

Collaboration to create new methods on AB SCIEX QTRAP 5500 System for faster and broader quantitative analysis in support of metabolomics studies

A new avenue for Alzheimer’s

A new avenue for Alzheimer’s

MIT researchers say SIRT1, a gene implicated in aging, may control production of protein fragments that make up amyloid plaques

Diagnostics

Penning a pair of diagnostic deals

Penning a pair of diagnostic deals

Eurogentec enters into two agreements with BD Diagnostics regarding molecular diagnostics: one in technology transfer and the other in suppl

Korea collaboration is key for cancer research

Korea collaboration is key for cancer research

Pfizer forms research partnership with South Korea’s Samsung to analyze, treat liver cancer tumors

Cancer double-team

Cancer double-team

Novartis, Pathwork Diagnostics forge collaboration to develop and sell diagnostics

IRIS takes AlliedPath to personalized medicine

IRIS takes AlliedPath to personalized medicine

Company closes on acquisition, gains laboratory offering MDx services

Global News

A sure selection

A sure selection

Agilent Technologies and Wellcome Trust Sanger Institute develop all-exon target enrichment tool for next-generation sequencing

Easing the pain

Easing the pain

BioFocus and University of Bristol enter drug discovery collaboration in diabetes-related chronic neuropathic pain

A dowry to the seal the engagement

A dowry to the seal the engagement

Actelion obtains option to acquire privately held Trophos for just under $13 million

Tour of Italy

Tour of Italy

Aptuit, Siena Biotech forge strategic partnership for former GSK facility in Verona

Special Reports

Pharmacogenomics harnesses power of prediction, personalization

Pharmacogenomics harnesses power of prediction, personalization

Branch of pharmacology stands at the precipice of the era of personalized medicine in cancer treatment

Getting down to basics

Getting down to basics

Researchers dig deep into the genome, not just to establish the causes of cancer, but also the best approaches to treatment

Editor's Focus

When shareholders attack, it’s not just the news that suffers

When shareholders attack, it’s not just the news that suffers

It’s the phone call or e-mail that every publication editor dreads. It comes seconds before deadline time, as the content your editorial team has worked for the last month to produce is committed to print. It comes from a writer whose story has morphed so materially from its original state that it can’t run as planned—usually leaving a black hole in your layout to be filled at the eleventh hour.

Commentary

Guest Commentary: Prioritizing hits based on drug-target residence time

Guest Commentary: Prioritizing hits based on drug-target residence time

Amid the complexity and expense of the small-molecule drug discovery process, from identification and validation of a “drugable” target to the development of an understanding of the impact of pharmacogenomic differences in patient populations on drug action, lies the “hit-to-lead” process in which compounds that show activity in an assay system are iteratively improved upon through medicinal chemistry that is guided by more detailed assays and filtering criteria.

Patent News

Lilly loses method patent after use was disclosed in earlier patent

Lilly loses method patent after use was disclosed in earlier patent

Eli Lilly & Co. recently lost an appeal from a final judgment of the U.S. District Court for the Eastern District of Michigan, finding claims 2, 6, and 7 of U.S. Patent No. 5,464,826 invalid for obviousness-type double patenting over its earlier U.S. Patent No. 4,808,614. (See, Sun Pharmaceutical Industries v. Lilly, U.S. Court of Appeals for the Federal Circuit, 2010-1105).
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Latest Issue's Magazine Cover

Latest Issue  

• Volume 17 • Issue 10 • October 2021

October 2021

October 2021 Issue